Sentences with phrase «years of therapy in»

When given the opportunity during her early phases of the preparation for trial, he tells Jessica that he can give her three years of therapy in a few minutes.

Not exact matches

Each child may have more than a dozen doctor appointments in a typical year, Gerardo said, plus hours of therapy, including occupational and speech therapy, and more.

With over 25 different forms of yoga and 122 meditation therapies, the company has gained a lot of traction in four years

Physical therapy aimed at rebuilding neural pathways can often improve a patient's level of functioning in the months and years after a spinal cord injury.

Right now, the first CRISPR gene therapies are in development, but they are not built on a «standard stack» and require a lot of custom work for each indication - these therapies will be coming into the clinic and hopefully get approved the coming couple years, and after that there could be significantly more investment into standard tools.»

Gene therapy has been on a roll in the past year, with the FDA approving Spark Therapeutics» landmark gene therapy for an inherited form of blindness in December.

Swiss pharmaceutical giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

And a third, different kind of gene therapy from Spark Therapeutics — to treat a rare inherited form of blindness — is likely to be approved by the end of 2017, too, making this year a landmark for treatments that manipulate the body's own biological mechanisms in novel new ways to fight deadly diseases.

Instead of getting a better, updated therapy for a disease every decade or so, we might begin to see second - generation cell therapies in a few years.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Since Marathon won an approval to treat a condition that afflicts fewer than 200,000 Americans per year and has a dearth of treatment options (rather than trying to become an also - ran in the saturated steroid therapy field), it has carte blanche over the drug's pricing.

«It's one of the things we're the most proud of, and the most humbled by as well,» says Amberg, who was named the school's Therapy Volunteer of the Year in 2013.

«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»

The company is also seeking deeper inroads into rare diseases, with a number of assets in late - stage development, and last year it scored a major regulatory win when Europe approved its «bubble boy syndrome» gene therapy Strimvelis.

Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm - changing immunocellular therapy to cancer patients in dire need.

Regulators noted that they will require special training for anyone involved in delivering this therapy, while expanding the approval of Actemra (tocilizumab) to treat CAR T - cell - induced severe or life - threatening CRS in patients 2 years of age or older.

With major clinical successes in areas such as CAR - T, gene therapy, immune - oncology, cell therapy and gene editing, many see 2017 as the year that biotech really came of age.

Dendreon was first - to - market with its activated cellular therapy, Provenge ® in 2010 followed by a 7 year gap until Novartis» Kymriah ® was approved in August of 2017 which was shortly followed up by the approval of Kite Pharma's Yescata ® in November of 2017.

This biotech's first year as a publicly traded company has been a terrific ride on the back of an experimental oncology therapy that could have huge built - in demand.

Incyte's (NASDAQ: INCY) Jakafi racked up $ 1.1 billion in sales last year as the only targeted therapy for patients with myelofibrosis, but a majority of patients who take it eventually relapse.

Combine this with dozens of oncology and ant - inflammatory collaborations for potentially first - in - class therapies, and you have a recipe for double - digit annual sales growth for years to come.

Biotech companies that don't have new drugs or therapies in the pipeline yet (about 40 percent of all those that went public last year, in fact) tend to take advantage of an IPO window because they have serious cost burdens --- like multiple drug tests and regulatory approval --- that other VC - backed companies don't have.

Over the last 60 years the profession has progressed in the United States (and throughout the world), with the development of standards of training and a body of research to guide credentialed practitioners in the ethical practice of art therapy.

It does, and that's only because I've gone through this kind of three - year process of first the deconstruction, the sort of subsequent crisis of that emotionally, and then the many, many therapy sessions that enabled me to sort of realize, «I am really in crisis because I'm worried about what people are going to think.»

It took years of therapy, prayer, and spiritual counsel for the healing to totally manifest.26 years after she began her journey, she was able to take a huge leap forward and on her 50th birthday she enrolled in college to study software engineering....

Ever since her story was featured in Christianity Today nearly a year ago, Butterfield has become something of a celebrity within the conservative evangelical world, and every time I'm in conversation with someone about the potential dangers of «conversion therapy» (which seeks to change a person's sexual orientation through counseling and prayer), her name invariably comes up.

For our purposes, the medical and psychiatric therapies may be divided into three categories according to their purpose: (1) those therapies that aid in the physical rehabilitation of the person suffering from the effects of an acute binge and / or prolonged excessive drinking over many years; (2) those that help to keep the addictive cycle broken and thus maintain sobriety for sufficient time to allow other therapies to take effect; (3) those that aim at lessening the alcoholic's personality problems — both those that contributed to the causation of his addiction and those resulting from the interpersonal chaos of progressive alcoholism.

In one two - year follow - up study of 178 alcoholics, it was found that 24 percent of those who had received conditioned reflex therapy plus group therapy had improved; 26 percent of those who had had individual therapy plus group therapy had improved;

Brooke Fraser is another artist who gave us a taste of what is potentially in store for this year when she released her much anticipated single «Therapy» last fall.

As a psychiatrist who has practiced and taught psychodynamic psychotherapy for years, I know that this type of therapy is actually one of the last vestiges of non-deterministic treatment in the cynical, superficial world of modern mental health care.

Until the last few years, I did not sense the significance of psychosynthesis and therefore did not take time to explore this therapy in depth.

Lorena had suffered from recurrent periods, of mental depression during the past 12 years, had undergone shock therapy, and had spent six weeks in a mental health center in an effort to learn which antidepression medication could help her.

Some years ago, a group of psychiatrists had a group of medical students do «supportive therapy» in 20 - minute sessions.

After all, it was only three years from the time that femi and gays first zapped the APA at a behavior therapy session to the time that the Board of Trustees voted in 1973 to approve removing homi from the list of mental disorders.

A woman who punished a 9 year old boy by making him sit in a bathtub while she poured boiling water on him, to the point where he will require physical therapy and skin grafts and a host of reconstructive surgery, also making the boy clean the kitchen after she burned him.

This was several years before I formally entered into therapy (long story there) and hadn't thought about the idea of work - life balance in any sort of depth.

After a year and a half of group therapy, of steering clear of the lifers and other hardened criminals who lived in the same cellblocks with addicts and of playing basketball in the prison yard, Manigault was paroled.

Jonny, now about eight years old, lives in San Francisco with Cris Cohen and Jennifer Long, longtime pit bull rescue volunteers, who quickly recognized his way with children and had him certified as a therapy dog within a year of taking him in.

After Vick and others were convicted on federal charges of trafficking and sponsoring fighting dogs, Jonny won a Most Beautiful Dog in the Country contest in 2012, had a Gund plush toy created in his likeness and last week was recognized for his work as a therapy dog with a new award: ASPCA Dog of the Year.

After so many years in the criminal justice system, after so many years of counseling and therapy, Watson has reached this ineluctable conclusion: He should die within these walls that now confine him.

So Leroy called his daughter, whose own husband had nearly died in a car accident eight years earlier, his injuries so extreme he had spent 76 days in the hospital and needed 29 screws and three plates and years of physical therapy to overcome a traumatic brain injury.

While I'm sure Boldt means well — as a mom myself, we always mean well — she may be forgetting that the couple, who announced their divorce this past July after 10 years of marriage and after having three children together — Violet, 10, Seraphina, 6, and Samuel, 3 — had been in marital therapy since allegedly splitting nearly three years ago.

I'm fourteen years old starting my road to recovery and it's very fearing and to know that I have to live with it scares the living daylight a out of me I can't speak much about my cognitive behavior therapy because I've only really doing assements but I'm writing this for myself and yourself I haven't always been religious but in times of fear and need know that you aren't alone God is always there and even wen your in your worse state I usally just lay down meditate a bit and speak to my father God and he always gives me a sense of relief this past week I feel like I have been a constant circle of fear but I would always freak out and be scared for no reason but just know that more than 44 million people have this you are br alone and one day you will meet your savior Jesus christ he put you in a test of life and he's going to congratulate you, you must wait for him and on another note if any one knows how to deal with the fear of the future or staying in a constant state please email me at [email protected] thank you so much everyone and there is a recovery maybe but today or Tommie but you will overcome

Three years ago, right around the publication of her first book, Carry On, Warrior, she confessed that she and her husband, Craig, were separating over something he disclosed when they were in therapy.

We have been in therapy for 5 years now!!!! Nothing has helped & all of the therapists have said itshis issue & he is very detached & passive.

She completed her training at Novalis School for Speech and Drama and at the School for the Art of Speech and Speech Therapy (both in Germany); post-graduate year at the Goetheanum, Switzerland.

A study from 2010 acknowledged, yes, «in the short - term, kids go through a one - to two - year crisis period when their parents divorce,» but the idea of staying together for the kids is problematic, especially if it's a high - conflict family, and that previous research indicating people should stay together «has been plagued by many data problems — reliance on small samples derived from one therapy clinic, retrospective reports, and cross sectional data.»

Allie Bowne Schreiner is a licensed marriage and family therapist with over nine years of experience practicing therapy with children, adolescents, adults and families and 20 years of experience working with children and families in various capacities.

I've used them with infants in early intervention therapy, and they have also come in handy for promoting my own son's development during his first years of life.